胸腺肽-α1预防卒中相关性肺炎的临床观察

Clinical observation of thymosin-α1 in prevention of stroke associated pneumonia

目的分析胸腺肽-α1预防卒中相关性肺炎(SAP)的有效性和安全性。方法将2014年1月至2017年1月该院收治的84例缺血性脑卒中患者采用随机数字表法分为研究组(45例)和对照组(39例)。对照组根据相关诊治指南实施标准治疗,研究组在标准治疗基础上联合胸腺肽-α1治疗,对比两组患者SAP发生率和治疗的不良事件。结果研究组患者中发生SAP 4例(8.89%),对照组发生8例(20.51%);两组患者SAP发生率比较,差异无统计学意义(χ2=2.305,P=0.129)。但研究组患者中伴高血压、糖尿病及冠心病患者SAP发生率[4.88%(2/41)]明显低于对照组[21.21%(7/33)],差异有统计学意义(χ2=4.566,P=0.033)。两组患者中均无发生3级以上不良事件者,两组患者各治疗相关不良事件发生率比较,差异均无统计学意义(P>0.05)。结论胸腺肽-α1预防SAP是安全、有效的。

Objective To investigate the efficacy and safety of thymosin-α1 in the prevention of stroke-associatedpneumonia（SAP）.Methods A total of 84 patients with ischemic stroke admitted to our hospital from January 2014 to January2017 were randomly divided into study group（45 cases）and control group（39 cases）.The control group was treated accordingto the standard treatment guidelines.The study group combined with thymosin-α1 on the basis of standard treatment and com-pared the incidence of SAP in the two groups and the adverse events of treatment.Results Among the patients in the studygroup,there were 4 cases of SAP（8.89%）,and 8 cases（20.51%）in the control group.There was no significant difference inthe incidence of SAP in the two groups（χ2=2.305,P=0.129）.However,the incidence of SAP in patients with hypertension,dia-betes and coronary heart diseasein the study group [4.88%（2/41）] was significantly lower than that of the control group[21.21%（7/33）],the difference was statistically significant（χ2=4.566,P=0.033）.Conclusions Thymosin-α1 injection was ef-fective and safe in the prevention of SAP.